TN2013000533A1 - Topical ophthalmological pharmaceutical composition containing regorafenib - Google Patents

Topical ophthalmological pharmaceutical composition containing regorafenib

Info

Publication number: TN2013000533A1
Authority: TN; Tunisia
Prior art keywords: pharmaceutical composition; composition containing; ophthalmological pharmaceutical; topical ophthalmological; containing regorafenib
Prior art date: 2011-06-28

Application number

TNP2013000533A

Other languages

English (en)

Inventor

Georges Degenfeld

Julia Freundlieb

Claudia Hirth-Dietrich

Joerg Keldenich

Juergen Klar

Uwe Muenster

Andreas Ohm

Annett Richter

Bernd Riedl

Michael Bottger

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-28

Filing date

2013-12-27

Publication date

2015-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-27 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2015-03-30 Publication of TN2013000533A1 publication Critical patent/TN2013000533A1/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

TNP2013000533A 2011-06-28 2013-12-27 Topical ophthalmological pharmaceutical composition containing regorafenib TN2013000533A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11171719		2011-06-28
EP12155281		2012-02-14
PCT/EP2012/062365 WO2013000917A1 (fr)	2011-06-28	2012-06-26	Composition pharmaceutique topique ophtalmologique contenant du régorafénib

Publications (1)

Publication Number	Publication Date
TN2013000533A1 true TN2013000533A1 (en)	2015-03-30

Family

ID=46456546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000533A TN2013000533A1 (en)	2011-06-28	2013-12-27	Topical ophthalmological pharmaceutical composition containing regorafenib

Country Status (26)

Country	Link
US (1)	US20140296301A1 (fr)
EP (1)	EP2726059A1 (fr)
JP (1)	JP5998213B2 (fr)
KR (1)	KR20140048218A (fr)
CN (1)	CN103889399A (fr)
AP (1)	AP2013007335A0 (fr)
AR (1)	AR086800A1 (fr)
AU (1)	AU2012277905A1 (fr)
BR (1)	BR112013033831A2 (fr)
CA (1)	CA2840329A1 (fr)
CL (1)	CL2013003700A1 (fr)
CO (1)	CO6920289A2 (fr)
CR (1)	CR20130693A (fr)
CU (1)	CU24163B1 (fr)
DO (1)	DOP2013000314A (fr)
EA (1)	EA201400064A1 (fr)
EC (1)	ECSP13013106A (fr)
GT (1)	GT201300322A (fr)
HK (1)	HK1197176A1 (fr)
MX (1)	MX2013015287A (fr)
PE (1)	PE20141031A1 (fr)
PH (1)	PH12013502691A1 (fr)
TN (1)	TN2013000533A1 (fr)
UY (1)	UY34166A (fr)
WO (1)	WO2013000917A1 (fr)
ZA (1)	ZA201400646B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006034797A1 (fr)	2004-09-29	2006-04-06	Bayer Healthcare Ag	Forme thermodynamiquement stable de tosylate de bay 43-9006
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) *	2012-12-21	2014-07-31	Bayer Healthcare Llc	Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (fr) *	2013-07-24	2015-01-29	Dr. Reddys Laboratories Limited	Formes polymorphes cristallines du régorafénib et méthodes de préparation de la forme polymorphe i du régorafénib
CN103923000A (zh) *	2014-01-29	2014-07-16	苏州晶云药物科技有限公司	几种新晶型及其制备方法
CN104546776B (zh) *	2015-02-10	2017-08-22	杭州朱养心药业有限公司	瑞戈非尼片剂药物组合物和制法
CN108135737B (zh) *	2015-06-06	2021-11-05	拨云生物医药科技(广州)有限公司	用于治疗翼状胬肉的组合物和方法
WO2017210130A1 (fr)	2016-06-02	2017-12-07	Cloudbreak Therapeutics, Llc	Compositions et procédés d'utilisation de nintedanib pour améliorer le taux de réussite de la chirurgie du glaucome

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2732222B1 (fr) *	1995-03-28	1997-04-25	Oreal	Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
EA020569B1 (ru) *	2002-05-28	2014-12-30	Такеда Гмбх	Применение рофлумиласта и его производных и фармацевтический препарат для местного применения
EP1663978B1 (fr) *	2003-07-23	2007-11-28	Bayer Pharmaceuticals Corporation	Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
MX2007014083A (es)	2005-05-10	2008-02-07	Alcon Inc	Formulaciones en suspension que comprenden un principio activo, un agente tensioactivo de poloxamero o meroxapol y un glicol, su uso en la fabricacion de un medicamento para tratar trastornos oftalmicos.
US20060292203A1 (en)	2005-06-08	2006-12-28	Targegen, Inc.	Methods and compositions for the treatment of ocular disorders
MX2008006379A (es)	2005-11-29	2009-03-03	Smithkline Beecham Corp	Metodo de tratamiento.
JP2009519267A (ja) *	2005-12-15	2009-05-14	バイエル・ヘルスケア・アクチェンゲゼルシャフト	炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア
JP2009521493A (ja)	2005-12-23	2009-06-04	アルコン，インコーポレイテッド	眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
WO2008027341A2 (fr)	2006-08-30	2008-03-06	Merck & Co., Inc.	Formulations ophtalmiques locales
AR062927A1 (es)	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2008308489A (ja) *	2007-05-11	2008-12-25	Santen Pharmaceut Co Ltd	ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
DE102007055341A1 (de) *	2007-11-19	2009-05-20	Bayer Animal Health Gmbh	Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
WO2010127029A1 (fr)	2009-05-01	2010-11-04	Ophthotech Corporation	Procédés de traitement ou de prévention de maladies ophtalmologiques
US20120165354A1 (en)	2009-07-16	2012-06-28	Glaxo Wellcome Manufacturing Pte Ltd.	Treatment method

2012
- 2012-06-26 PE PE2013002872A patent/PE20141031A1/es not_active Application Discontinuation
- 2012-06-26 BR BR112013033831A patent/BR112013033831A2/pt not_active IP Right Cessation
- 2012-06-26 AU AU2012277905A patent/AU2012277905A1/en not_active Abandoned
- 2012-06-26 CN CN201280042504.9A patent/CN103889399A/zh active Pending
- 2012-06-26 EP EP12731396.3A patent/EP2726059A1/fr not_active Withdrawn
- 2012-06-26 EA EA201400064A patent/EA201400064A1/ru unknown
- 2012-06-26 CA CA2840329A patent/CA2840329A1/fr not_active Abandoned
- 2012-06-26 WO PCT/EP2012/062365 patent/WO2013000917A1/fr active Application Filing
- 2012-06-26 CU CU20130168A patent/CU24163B1/es active IP Right Grant
- 2012-06-26 MX MX2013015287A patent/MX2013015287A/es not_active Application Discontinuation
- 2012-06-26 AP AP2013007335A patent/AP2013007335A0/xx unknown
- 2012-06-26 PH PH1/2013/502691A patent/PH12013502691A1/en unknown
- 2012-06-26 US US14/128,356 patent/US20140296301A1/en not_active Abandoned
- 2012-06-26 JP JP2014517661A patent/JP5998213B2/ja not_active Expired - Fee Related
- 2012-06-26 KR KR1020147002095A patent/KR20140048218A/ko not_active Withdrawn
- 2012-06-27 UY UY0001034166A patent/UY34166A/es not_active Application Discontinuation
- 2012-06-28 AR ARP120102339A patent/AR086800A1/es active Pending
2013
- 2013-12-20 CR CR20130693A patent/CR20130693A/es unknown
- 2013-12-23 CL CL2013003700A patent/CL2013003700A1/es unknown
- 2013-12-23 GT GT201300322A patent/GT201300322A/es unknown
- 2013-12-24 EC EC2013013106A patent/ECSP13013106A/es unknown
- 2013-12-26 DO DO2013000314A patent/DOP2013000314A/es unknown
- 2013-12-26 CO CO13300167A patent/CO6920289A2/es not_active Application Discontinuation
- 2013-12-27 TN TNP2013000533A patent/TN2013000533A1/fr unknown
2014
- 2014-01-27 ZA ZA2014/00646A patent/ZA201400646B/en unknown
- 2014-10-22 HK HK14110517A patent/HK1197176A1/xx unknown

Also Published As

Publication number	Publication date
JP2014518233A (ja)	2014-07-28
UY34166A (es)	2013-01-31
CR20130693A (es)	2016-05-02
NZ619229A (en)	2016-04-29
CO6920289A2 (es)	2014-04-10
AU2012277905A1 (en)	2014-01-16
MX2013015287A (es)	2014-03-31
CN103889399A (zh)	2014-06-25
CU24163B1 (es)	2016-03-31
WO2013000917A1 (fr)	2013-01-03
CU20130168A7 (es)	2014-04-24
BR112013033831A2 (pt)	2017-02-14
DOP2013000314A (es)	2014-04-15
US20140296301A1 (en)	2014-10-02
GT201300322A (es)	2014-11-13
PE20141031A1 (es)	2014-08-21
CL2013003700A1 (es)	2014-07-18
AP2013007335A0 (en)	2013-12-31
AU2012277905A8 (en)	2014-01-30
CA2840329A1 (fr)	2013-01-03
EA201400064A1 (ru)	2014-05-30
ZA201400646B (en)	2015-11-25
AR086800A1 (es)	2014-01-22
KR20140048218A (ko)	2014-04-23
PH12013502691A1 (en)	2017-08-23
EP2726059A1 (fr)	2014-05-07
HK1197176A1 (en)	2015-01-09
ECSP13013106A (es)	2014-01-31
JP5998213B2 (ja)	2016-09-28

Publication	Publication Date	Title
PH12015500460B1 (en)	2015-04-20	Coated pharmaceutical composition containing regorafenib
WO2013188273A8 (fr)	2014-02-13	Composition pharmaceutique ophtalmique topique contenant de l'axitinib
WO2013188268A8 (fr)	2014-02-13	Composition pharmaceutique ophtalmique topique contenant du pazopanib
TN2013000533A1 (en)	2015-03-30	Topical ophthalmological pharmaceutical composition containing regorafenib
WO2013188283A8 (fr)	2017-03-23	Composition pharmaceutique ophtalmique topique contenant du sunitinib
PH12015500587A1 (en)	2015-05-11	Combination of regorafenib and acetylsalicylic acid for treating cancer
EA033544B1 (ru)	2019-10-31	Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MX2015016421A (es)	2016-03-03	Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2013012588A (es)	2014-05-20	Inhibidores de cinasa.
MX2014000964A (es)	2014-03-27	Derivados aza heterociclicos sustituidos.
MX2017013099A (es)	2018-01-26	Metodos para el tratamiento de trastornos inflamatorios.
TN2015000280A1 (en)	2016-10-03	Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
IN2013DN02555A (fr)	2015-08-07
WO2013188279A8 (fr)	2014-02-06	Composition pharmaceutique ophtalmique topique contenant du cediranib
IN2015MN00045A (fr)	2015-10-16
MX2014003584A (es)	2014-04-25	Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2011008857A (es)	2011-09-30	Derivados de oxiindol con actividad agonistica del receptor de motilina.
WO2012176163A3 (fr)	2013-02-21	Composés pour le traitement de cancers associés à un papillomavirus humain
DOP2015000049A (es)	2015-04-15	Composición farmacéutica recubierta que contiene regorafenib